EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is entered into as of February 23, 2015 (the “Effective Date”), by and between Peter Flynn (“Executive”) and Orexigen Therapeutics, Inc. (the “Company”).
Amendment No. 1 to Employment Agreement FEBRUARY 26, 2016Employment Agreement • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
This Amendment No. 1 is intended to modify the Employment Agreement (the “Agreement”) dated February 23, 2015 by and between Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) with its principal place of business located at 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 and Peter Flynn (“Executive”). All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.
Amendment No. 3 to Employment Agreement October 13, 2017Employment Agreement • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
Reference is made to the Employment Agreement (the “Agreement”) dated February 3, 2015 by and between Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) with its principal place of business located at 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 and Jason Keyes (“Executive”), and Amendment No. 2 to the Employment Agreement dated June 16, 2016 (the “Second Amendment”). All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.
Amendment No. 2 to Employment Agreement October 13, 2017Employment Agreement • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
Reference is made to the Employment Agreement (the “Agreement”) dated December 1, 2015 by and between Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) with its principal place of business located at 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 and Thomas Lynch (“Executive”), and Amendment No. 1 to the Employment Agreement dated February 2, 2016 (the “First Amendment”). All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.
FIFTH AMENDMENT TO LEASELease • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
THIS FIFTH AMENDMENT TO LEASE ("Fifth Amendment") is made and entered into as of September 11, 2017, by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, as successor-in-interest to Mullrock 3 Torrey Pines, LLC, a Delaware limited liability company ("Landlord") and OREXIGEN THERAPEUTICS, INC., a Delaware corporation ("Tenant").
Amendment No. 3 to Employment Agreement October 13, 2017Employment Agreement • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
Reference is made to the Employment Agreement (the “Agreement”) dated March 30, 2015 by and between Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) with its principal place of business located at 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 and Thomas Cannell (“Executive”), and Amendment No. 2 to the Employment Agreement dated June 16, 2016 (the “Second Amendment”). All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.
Orexigen Therapeutics, Inc.Retention Agreement • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
You are an important part of Orexigen Therapeutics, Inc. (the “Company”), and we recognize that your engagement and commitment are critical to the Company’s success. We value the contributions you make to our organization and are pleased to offer you the following Retention Agreement (the “Retention Agreement”). Certain capitalized terms used in this Retention Agreement are defined in Section V below.
Amendment No. 3 to Second Amended and restated Employment Agreement October 13, 2017Employment Agreement • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
Reference is made to the Second Amended and Restated Employment Agreement (the “Agreement”) dated June 14, 2011 by and between Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) with its principal place of business located at 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 and Michael Narachi (“Executive”), and Amendment No. 2 to the Second Amended and Restated Employment Agreement dated February 4, 2016 (the “Second Amendment”). All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.
FOURTH AMENDMENT TO LEASELease • November 14th, 2017 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO LEASE ("Fourth Amendment") is made and entered into as of October 25, 2016, by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, as successor-in-interest to Mullrock 3 Torrey Pines, LLC, a Delaware limited liability company ("Landlord") and OREXIGEN THERAPEUTICS, INC., a Delaware corporation ("Tenant").
